Episurf Medical receives CE mark for Episealer® Talus and Talus Osteotomy Guide
Episurf Medical (NASDAQ: EPIS B) announces that today the company has received CE mark for Episealer® Talus and Talus Osteotomy Guide.
Episealer® Talus is an implant technology intended for osteochondral lesions of the talar dome of the ankle joint. Talus Osteotomy Guide is an individualised osteotomy guide that is intended to help surgeons finding the correct position and depth of the cut when performing a medial malleolar osteotomy to access the talar dome.
“We have been looking forward to this and we are enormously happy to finally have the CE mark in place. It is fantastic that we now offer our implant technology not only for knees but also for these difficult to treat ankle injuries. Of course, this is also a significant commercial opportunity for us. We now have three commercial legs; knee joint, ankle and imaging” says Pål Ryfors, CEO Episurf Medical.
“There is a great demand for this implant, as there are few alternatives for lesions in the ankle. In many cases, patients with these injuries are forced to undergo joint fusion. It feels fantastic to finally be able to offer our solution. This is an example that Episurf's technology in principle can be applied to all joints” comments Leif Ryd, Senior Medical Advisor, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11.40 CET on 8 January 2020.